IBO (Impact BioMedical) Total Operating Expense: $4.71 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

IBO Impact BioMedical Inc IBO
10 GF Score
Price $0.44
! 6 Warning Signs
View Full Analysis

What is Impact BioMedical Total Operating Expense?

Impact BioMedical IBO -0.89% 10 Total Operating Expense is $4.71 Mil as of Jun. 2026. GuruFocus rates IBO with a GF Score™ of 10/100. The stock has 6 warning signs investors should review.

Impact BioMedical's Total Operating Expense for the three months ended in Jun. 2026 was $0.70 Mil. Impact BioMedical's Total Operating Expense for the trailing twelve months (TTM) ended in Jun. 2026 was $4.71 Mil.

Impact BioMedical Total Operating Expense Related Terms

Impact BioMedical Total Operating Expense Historical Data

* Premium members only.

The historical data trend for Impact BioMedical's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Impact BioMedical Total Operating Expense Chart

Impact BioMedical Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Operating Expense
Get a 7-Day Free Trial 3.45 3.45 4.03 3.40 3.88

Impact BioMedical Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Total Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.16 0.97 0.74 2.30 0.70
IBO
10GF Score
Impact BioMedical Inc IBO
Total Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Impact BioMedical Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $4.71 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of $4.71 Mil mean?
Impact BioMedical (IBO) has a Total Operating Expense of $4.71 Mil as of Jun. 2026. Total operating expense is the primary recurring expense associated with central operations. View historical data on Impact BioMedical and its competitors.
Is Impact BioMedical's Total Operating Expense too high?
Impact BioMedical's current Total Operating Expense is $4.71 Mil. Overall, Impact BioMedical has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Impact BioMedical's Total Operating Expense compare to ATYR and MCRB?
Impact BioMedical's Total Operating Expense of $4.71 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Biotechnology company?
A good Total Operating Expense depends on the Biotechnology industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on Impact BioMedical and its competitors. Impact BioMedical's current Total Operating Expense is $4.71 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Impact BioMedical stock overvalued right now?
Impact BioMedical (IBO) has a current Total Operating Expense of $4.71 Mil. The current Total Operating Expense is $4.71 Mil. Impact BioMedical's overall GF Score™ is 10/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For Impact BioMedical (IBO), the current Total Operating Expense is $4.71 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Impact BioMedical Business Description

Address 1400 Broadfield Boulevard, Suite 130, Houston, TX, USA, 77084
Impact BioMedical Inc focuses on the advancement of drug discovery and prevention, inhibition, and treatment of neurological, oncological, and immune-related diseases. The company is also developing open-air defense initiatives, which curb transmission of air-borne infectious diseases, such as tuberculosis and influenza. Its technologies inlcude Linebacker, Laetose, 3F, and Equivir.
10GF Score

Get the complete analysis for IBO

Total Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.44
Price